{{Rsnum
|rsid=11887120
|Gene=DNMT3A
|Chromosome=2
|position=25262866
|Orientation=plus
|GMAF=0.4752
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=DNMT3A
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 35.4 | 50.4 | 14.2
| HCB | 23.4 | 54.7 | 21.9
| JPT | 29.2 | 51.3 | 19.5
| YRI | 31.3 | 46.3 | 22.4
| ASW | 19.3 | 49.1 | 31.6
| CHB | 23.4 | 54.7 | 21.9
| CHD | 21.1 | 45.9 | 33.0
| GIH | 49.0 | 39.0 | 12.0
| LWK | 14.5 | 48.2 | 37.3
| MEX | 19.0 | 50.0 | 31.0
| MKK | 23.7 | 50.6 | 25.6
| TSI | 41.2 | 39.2 | 19.6
| HapMapRevision=28
}}

{{PMID|18381459|OA=1
}} 829 Caucasian cases with primary epithelial ovarian cancer and 941 frequency-matched unaffected controls 
Three SNPs in DNMT3A were associated with risk among multivitamin supplement users: 
*3' untranslated region (UTR) C>G ([[rs13420827]]: OR, 0.8; 95% CI, 0.6-1.0; P interaction = 0.006; FPRP = 0.54)
*intron 6 G>A ([[rs11887120]]: OR, 0.8; 95% CI, 0.7-1.0; P interaction = 0.007; FPRP = 0.57)
*intron 22 A>T ([[rs11695471]]: OR, 1.2; 95% CI, 1.0-1.5; P interaction = 0.01; FPRP = 0.66)

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}